The global Live Vaccines Market was worth USD 16.14 billion in 2019 and is projected to expand at a CAGR of 6.6% to reach over USD 26.59 billion by 2027. The market is being driven by the growing prevalence of infectious diseases like polio and varicella, rising awareness among the population, increasing government initiatives, and growing healthcare spending capacity of individuals.

Live vaccines are created by weakening disease-causing viruses or bacteria through repeated culturing. These vaccines create an immune response by replicating the virus or vaccine within the individual's body.

Get a free sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/2078

Governmental initiatives such as the Indian Government’s Pulse Polio program, which aims to vaccinate 100% of the population against polio, contribute to an increase in awareness among the population. The Global Polio Eradication Initiative is also funded by various public and private donors, and is estimated to require USD 4.2 billion in funding from 2013-2019.

There are several key players in the live vaccines market, including:

1.     Merck & Co., Inc.

2.     Sanofi Pasteur

3.     GlaxoSmithKline plc

4.     Pfizer Inc.

5.     Serum Institute of India Pvt. Ltd.

6.     Emergent BioSolutions Inc.

7.     AstraZeneca

8.     Bavarian Nordic

9.     CSL Limited

10.Indian Immunologicals Limited

Despite the program's success, polio remains endemic in countries such as Afghanistan, Nigeria, and Pakistan. Yellow fever is estimated to be endemic in more than 30 African countries and around 11 Latin American countries, with approximately 200,000 new cases appearing each year. As the yellow fever vaccine is the only available treatment for the disease, its high prevalence is contributing to the growth of the global live vaccines market.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/2078

Recently, wealthier European countries such as England and Wales lost their measles-free status due to a registration of newer cases of measles, creating an emerging market for the measles live vaccine in the region. Live vaccines are preferred over other types of vaccines as they boost an individual's own immune response, and a single dose of vaccination is sufficient to produce lifetime immunity against the respective disease.

Technologically advanced live vaccines, such as live recombinant vaccines, use attenuated viruses or bacteria as vectors to target specific diseases. The Vaccinia virus was the first live recombinant vaccine used for the treatment of smallpox. Influenza, hepatitis B, and rabies are other examples of popular live recombinant vaccines.

However, there are some factors that are expected to negatively affect the growth of the live vaccines market in the forecast period, such as side effects like contraindication in pregnancy, the possibility of complications in case individuals are under immunosuppressant medications or have lowered immunity, and the difficulty of storing live vaccines.

The global live vaccines market is segmented by type into bacterial and viral vaccines. The viral segment is expected to be the fastest-growing segment with the largest market share, followed by the bacterial segment. The market is also segmented by route of administration, with the injection pathway leading the global market and generating revenue of USD 6.27 billion in 2019. The market is further segmented by application into measles and BCG, with the measles segment accounting for a significant share of the global market in 2019 due to its high prevalence rate worldwide.

North America is the leading region for the live vaccines market, followed by Europe. North America has a large number of research and development centers and biopharmaceutical companies, contributing to its high revenue generation. Asia-Pacific is estimated to be the fastest-growing regional segment, accounting for market revenue of USD 3.44 billion in 2019 and a CAGR of 7.2% during the forecast period, owing to the growing incidence of infectious diseases, significant birth rate in emerging countries of Asia Pacific, improved regulatory framework, strong worldwide distribution network of live vaccines manufacturers, and rising public awareness related to benefits offered by live vaccines in the eradication of infectious diseases.

Request customization of the report @

https://www.reportsanddata.com/request-customization-form/2078

Thank you for reading our report. Please connect with us to know more about the report and its customization feature. Our team will ensure the report is well suited to meet your requirements.

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs